Western Midstream Edges Higher on Distribution
Western Midstream Partners, LP (NYSE: WES) shares cleared breakeven Friday, after the company announced that the board of directors of its general partner declared a quarterly cash distribution of $0.8750 per unit for the fourth quarter of 2024, or $3.50 on an annualized basis, which is in-line with the prior quarter's Base Distribution. WES's fourth-quarter 2024 Base Distribution is payable on February 14, 2025, to unitholders of record at the close of business on February 3, 2025.The Partnership plans to report its fourth-quarter and full-year 2024 results after market close on Wednesday, February 26, 2025. Management will host a conference call on Thursday, February 27, 2025, at 1:00 p.m. Central (2:00 p.m. Eastern) to discuss the Partnership's quarterly and full-year results. Participants are encouraged to dial into the conference call ten to fifteen minutes before the scheduled start time to avoid any delays entering the call.Western Midstream is a master limited partnership formed to develop, acquire, own, and operate midstream assets. With midstream assets located in Texas, New Mexico, Colorado, Utah, and Wyoming, WES is engaged in the business of gathering, compressing, treating, processing, and transporting natural gas; gathering, stabilizing, and transporting condensate, natural-gas liquids, and crude oil; and gathering and disposing of produced water for its customers. WES gathered eight cents to $42.51.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


